BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 19505505)

  • 1. Comparison of phenotype of gammadelta T cells generated using various cultivation methods.
    Mehrle S; Watzl C; von Lilienfeld-Toal M; Amoroso A; Schmidt J; Märten A
    Immunol Lett; 2009 Jun; 125(1):53-8. PubMed ID: 19505505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
    Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
    Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of IL-18 on expansion of gammadelta T cells stimulated by zoledronate and IL-2.
    Li W; Kubo S; Okuda A; Yamamoto H; Ueda H; Tanaka T; Nakamura H; Yamanishi H; Terada N; Okamura H
    J Immunother; 2010 Apr; 33(3):287-96. PubMed ID: 20445349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and function of PD-1 in human γδ T cells that recognize phosphoantigens.
    Iwasaki M; Tanaka Y; Kobayashi H; Murata-Hirai K; Miyabe H; Sugie T; Toi M; Minato N
    Eur J Immunol; 2011 Feb; 41(2):345-55. PubMed ID: 21268005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune modulation by zoledronic acid in human myeloma: an advantageous cross-talk between Vγ9Vδ2 T cells, αβ CD8+ T cells, regulatory T cells, and dendritic cells.
    Castella B; Riganti C; Fiore F; Pantaleoni F; Canepari ME; Peola S; Foglietta M; Palumbo A; Bosia A; Coscia M; Boccadoro M; Massaia M
    J Immunol; 2011 Aug; 187(4):1578-90. PubMed ID: 21753152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Copulsing tumor antigen-pulsed dendritic cells with zoledronate efficiently enhance the expansion of tumor antigen-specific CD8+ T cells via Vgamma9gammadelta T cell activation.
    Takahara M; Miyai M; Tomiyama M; Mutou M; Nicol AJ; Nieda M
    J Leukoc Biol; 2008 Mar; 83(3):742-54. PubMed ID: 18156189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
    Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
    Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Essential requirements of zoledronate-induced cytokine and γδ T cell proliferative responses.
    Nussbaumer O; Gruenbacher G; Gander H; Komuczki J; Rahm A; Thurnher M
    J Immunol; 2013 Aug; 191(3):1346-55. PubMed ID: 23794630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates.
    Sanders JM; Ghosh S; Chan JM; Meints G; Wang H; Raker AM; Song Y; Colantino A; Burzynska A; Kafarski P; Morita CT; Oldfield E
    J Med Chem; 2004 Jan; 47(2):375-84. PubMed ID: 14711309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral blood gamma-delta T cells in advanced-stage cancer patients.
    Bilgi O; Karagoz B; Turken O; Kandemir EG; Ozturk A; Gumus M; Yaylaci M
    Adv Ther; 2008 Mar; 25(3):218-24. PubMed ID: 18369538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defective gammadelta T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patients.
    Gaafar A; Aljurf MD; Al-Sulaiman A; Iqniebi A; Manogaran PS; Mohamed GE; Al-Sayed A; Alzahrani H; Alsharif F; Mohareb F; Ajarim D; Tabakhi A; Al-Hussein K
    Exp Hematol; 2009 Jul; 37(7):838-48. PubMed ID: 19446661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The probiotic Escherichia coli strain Nissle 1917 induces gammadelta T cell apoptosis via caspase- and FasL-dependent pathways.
    Guzy C; Paclik D; Schirbel A; Sonnenborn U; Wiedenmann B; Sturm A
    Int Immunol; 2008 Jul; 20(7):829-40. PubMed ID: 18448456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and characterization of Foxp3(+) gammadelta T cells in mouse and human.
    Kang N; Tang L; Li X; Wu D; Li W; Chen X; Cui L; Ba D; He W
    Immunol Lett; 2009 Aug; 125(2):105-13. PubMed ID: 19539651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toll-like receptor expression and function in subsets of human gammadelta T lymphocytes.
    Pietschmann K; Beetz S; Welte S; Martens I; Gruen J; Oberg HH; Wesch D; Kabelitz D
    Scand J Immunol; 2009 Sep; 70(3):245-55. PubMed ID: 19703014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells.
    Muraro M; Mereuta OM; Carraro F; Madon E; Fagioli F
    Cell Immunol; 2007 Oct; 249(2):63-72. PubMed ID: 18163982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer.
    Nagamine I; Yamaguchi Y; Ohara M; Ikeda T; Okada M
    Hiroshima J Med Sci; 2009 Mar; 58(1):37-44. PubMed ID: 19400555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo application of mAb directed against the gammadelta TCR does not deplete but generates "invisible" gammadelta T cells.
    Koenecke C; Chennupati V; Schmitz S; Malissen B; Förster R; Prinz I
    Eur J Immunol; 2009 Feb; 39(2):372-9. PubMed ID: 19130484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma.
    Burjanadzé M; Condomines M; Reme T; Quittet P; Latry P; Lugagne C; Romagne F; Morel Y; Rossi JF; Klein B; Lu ZY
    Br J Haematol; 2007 Oct; 139(2):206-16. PubMed ID: 17897296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gammadelta T cell development--having the strength to get there.
    Pennington DJ; Silva-Santos B; Hayday AC
    Curr Opin Immunol; 2005 Apr; 17(2):108-15. PubMed ID: 15766668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity.
    Mattarollo SR; Kenna T; Nieda M; Nicol AJ
    Cancer Immunol Immunother; 2007 Aug; 56(8):1285-97. PubMed ID: 17265022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.